康弘药业：康柏西普眼用注射液收到药物临床试验补充申请批准通知书

Core Viewpoint - Kanghong Pharmaceutical's subsidiary, Kanghong Biotech, has received approval from the National Medical Products Administration for the clinical trial of its eye injection drug, Conbercept, aimed at treating vision loss caused by neovascular (wet) age-related macular degeneration (nAMD) [1] Group 1 - Kanghong Biotech is a wholly-owned subsidiary of Kanghong Pharmaceutical [1] - The approved drug, Conbercept, is specifically indicated for vision impairment due to nAMD [1]